jm2c01566_si_001.pdf (4.88 MB)
Discovery of Novel Acridane-Based Tubulin Polymerization Inhibitors with Anticancer and Potential Immunomodulatory Effects
journal contributionposted on 2022-12-14, 19:34 authored by Xiaopeng Peng, Yichang Ren, Wanyi Pan, Jin Liu, Jianjun Chen
A series of novel acridane-based tubulin polymerization inhibitors were designed, synthesized, and bioevaluated as anticancer agents. The most potent compound NT-6 exhibited high tubulin polymerization inhibitory activity (IC50 = 1.5 μM) and remarkable antiproliferative potency against four cancer cell lines with an average IC50 of 30 nM, better than colchicine and the hit compound 1f (IC50 of 65 and 126 nM, respectively). In addition, NT-6 (10 mg/kg) exerted excellent antitumor efficacy in a melanoma tumor model with a tumor growth inhibition (TGI) of 65.1% without apparent toxicity. Importantly, the combination of NT-6 with a small-molecule PD-L1 inhibitor NP-19 decreased tumor burden significantly (TGI% = 77.6%). Moreover, the combination of NT-6 with NP-19 enhanced the antitumor immune response, mediated by a decrease of PD-L1 expression levels and increased infiltration of antitumor CD8+ effector T cells in tumor tissues. Collectively, NT-6 represents a novel tubulin polymerization inhibitor with immunopotentiating effects.
without apparent toxicitysup >+ supremarkable antiproliferative potencyl1 expression levelstumor growth inhibitionmelanoma tumor modelpotential immunomodulatory effectsantitumor immune response1f bl1 inhibitor np50 sub6 btumor tissuesimmunopotentiating effectsantitumor cd86 %).respectively ).potent compoundnovel acridaneincreased infiltrationhit compound5 μm30 nm19 enhanced126 nm10 mg